MYC and prostate cancer: Dose-dependent effects were monitored in PC-3 prostate cancer cells, as well as in previously identified PPRH-sensitive AsPc-1 pancreatic cancer cells, where strong dose- and time-dependent effects on cell viability and growth and MYC transcription and translation were observed.